These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 23359498)

  • 61. Tyrosine kinase 2 modulates splenic B cells through type I IFN and TLR7 signaling.
    Bodega-Mayor I; Delgado-Wicke P; Arrabal A; Alegría-Carrasco E; Nicolao-Gómez A; Jaén-Castaño M; Espadas C; Dopazo A; de Luis EV; Martín-Gayo E; Gaspar ML; de Andrés B; Fernández-Ruiz E
    Cell Mol Life Sci; 2024 Apr; 81(1):199. PubMed ID: 38683377
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The JAK-inhibitor, JAB/SOCS-1 selectively inhibits cytokine-induced, but not v-Src induced JAK-STAT activation.
    Iwamoto T; Senga T; Naito Y; Matsuda S; Miyake Y; Yoshimura A; Hamaguchi M
    Oncogene; 2000 Sep; 19(41):4795-801. PubMed ID: 11032030
    [TBL] [Abstract][Full Text] [Related]  

  • 63. TYK2 rs34536443 polymorphism is associated with a decreased susceptibility to endometriosis-related infertility.
    Peluso C; Christofolini DM; Goldman CS; Mafra FA; Cavalcanti V; Barbosa CP; Bianco B
    Hum Immunol; 2013 Jan; 74(1):93-7. PubMed ID: 23000200
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Therapeutic Advantage of Tyk2 Inhibition for Treating Autoimmune and Chronic Inflammatory Diseases.
    Muromoto R; Shimoda K; Oritani K; Matsuda T
    Biol Pharm Bull; 2021; 44(11):1585-1592. PubMed ID: 34719635
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Differential requirements for JAK2 and TYK2 in T cell proliferation and IFN-gamma production induced by IL-12 alone or together with IL-18.
    Sugimoto N; Nakahira M; Ahn HJ; Micallef M; Hamaoka T; Kurimoto M; Fujiwara H
    Eur J Immunol; 2003 Jan; 33(1):243-51. PubMed ID: 12594853
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The thrombopoietin receptor c-MPL activates JAK2 and TYK2 tyrosine kinases.
    Sattler M; Durstin MA; Frank DA; Okuda K; Kaushansky K; Salgia R; Griffin JD
    Exp Hematol; 1995 Aug; 23(9):1040-8. PubMed ID: 7543416
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Tyrosine kinase 2 promotes sepsis-associated lethality by facilitating production of interleukin-27.
    Bosmann M; Strobl B; Kichler N; Rigler D; Grailer JJ; Pache F; Murray PJ; Müller M; Ward PA
    J Leukoc Biol; 2014 Jul; 96(1):123-31. PubMed ID: 24604832
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The human papilloma virus (HPV)-18 E6 oncoprotein physically associates with Tyk2 and impairs Jak-STAT activation by interferon-alpha.
    Li S; Labrecque S; Gauzzi MC; Cuddihy AR; Wong AH; Pellegrini S; Matlashewski GJ; Koromilas AE
    Oncogene; 1999 Oct; 18(42):5727-37. PubMed ID: 10523853
    [TBL] [Abstract][Full Text] [Related]  

  • 69. A single nucleotide polymorphism in Tyk2 controls susceptibility to experimental allergic encephalomyelitis.
    Spach KM; Noubade R; McElvany B; Hickey WF; Blankenhorn EP; Teuscher C
    J Immunol; 2009 Jun; 182(12):7776-83. PubMed ID: 19494301
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Differential utilization of Janus kinase-signal transducer activator of transcription signaling pathways in the stimulation of human natural killer cells by IL-2, IL-12, and IFN-alpha.
    Yu CR; Lin JX; Fink DW; Akira S; Bloom ET; Yamauchi A
    J Immunol; 1996 Jul; 157(1):126-37. PubMed ID: 8683106
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Catalytically Impaired TYK2 Variants are Protective Against Childhood- and Adult-Onset Systemic Lupus Erythematosus in Mexicans.
    Contreras-Cubas C; García-Ortiz H; Velázquez-Cruz R; Barajas-Olmos F; Baca P; Martínez-Hernández A; Barbosa-Cobos RE; Ramírez-Bello J; López-Hernández MA; Svyryd Y; Mutchinick OM; Baca V; Orozco L
    Sci Rep; 2019 Aug; 9(1):12165. PubMed ID: 31434951
    [TBL] [Abstract][Full Text] [Related]  

  • 72. TYK2 inhibition reduces type 3 immunity and modifies disease progression in murine spondyloarthritis.
    Gracey E; Hromadová D; Lim M; Qaiyum Z; Zeng M; Yao Y; Srinath A; Baglaenko Y; Yeremenko N; Westlin W; Masse C; Müller M; Strobl B; Miao W; Inman RD
    J Clin Invest; 2020 Apr; 130(4):1863-1878. PubMed ID: 32149730
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Viral infections in humans and mice with genetic deficiencies of the type I IFN response pathway.
    Meyts I; Casanova JL
    Eur J Immunol; 2021 May; 51(5):1039-1061. PubMed ID: 33729549
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Interferon-alpha-dependent activation of Tyk2 requires phosphorylation of positive regulatory tyrosines by another kinase.
    Gauzzi MC; Velazquez L; McKendry R; Mogensen KE; Fellous M; Pellegrini S
    J Biol Chem; 1996 Aug; 271(34):20494-500. PubMed ID: 8702790
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Tyrosine kinase 2 - Surveillant of tumours and bona fide oncogene.
    Leitner NR; Witalisz-Siepracka A; Strobl B; Müller M
    Cytokine; 2017 Jan; 89():209-218. PubMed ID: 26631911
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Comprehensive analysis of three TYK2 gene variants in the susceptibility to Chagas disease infection and cardiomyopathy.
    Leon Rodriguez DA; Acosta-Herrera M; Carmona FD; Dolade N; Vargas S; Echeverría LE; González CI; Martin J
    PLoS One; 2018; 13(1):e0190591. PubMed ID: 29304122
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Targeting the Tyrosine Kinase 2 (TYK2) Pseudokinase Domain: Discovery of the Selective TYK2 Inhibitor ABBV-712.
    Breinlinger E; Van Epps S; Friedman M; Argiriadi M; Chien E; Chhor G; Cowart M; Dunstan T; Graff C; Hardee D; Herold JM; Little A; McCarthy R; Parmentier J; Perham M; Qiu W; Schrimpf M; Vargo T; Webster MP; Wu F; Bennett D; Edmunds J
    J Med Chem; 2023 Oct; 66(20):14335-14356. PubMed ID: 37823891
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Human metapneumovirus inhibits IFN-β signaling by downregulating Jak1 and Tyk2 cellular levels.
    Ren J; Kolli D; Liu T; Xu R; Garofalo RP; Casola A; Bao X
    PLoS One; 2011; 6(9):e24496. PubMed ID: 21949722
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Distinct domains of the protein tyrosine kinase tyk2 required for binding of interferon-alpha/beta and for signal transduction.
    Velazquez L; Mogensen KE; Barbieri G; Fellous M; Uzé G; Pellegrini S
    J Biol Chem; 1995 Feb; 270(7):3327-34. PubMed ID: 7531704
    [TBL] [Abstract][Full Text] [Related]  

  • 80. ALL-associated JAK1 mutations confer hypersensitivity to the antiproliferative effect of type I interferon.
    Hornakova T; Chiaretti S; Lemaire MM; Foà R; Ben Abdelali R; Asnafi V; Tartaglia M; Renauld JC; Knoops L
    Blood; 2010 Apr; 115(16):3287-95. PubMed ID: 20167706
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.